10-Q: Quoin Pharma Q2 Loss Widens Amid R&D Surge

Quoin Pharmaceuticals Ltd. reported a significant increase in net loss for Q2 2025, driven by a substantial rise in research and development expenses, raising substantial doubt about its ability to continue as a going concern.

Summary

• Net loss for the three months ended June 30, 2025, increased to $3.7 million from $2.0 million in the prior year period.
• Net loss for the six months ended June 30, 2025, increased to $7.5 million from $4.3 million in the prior year period.
• Research and development expenses surged by 248.8% to $2.1 million for the three months and by 200.4% to $4.4 million for the six months ended June 30, 2025, primarily due to increased external expenditures on QRX003 clinical studies.
• Cash and cash equivalents stood at $1.7 million, with investments of $6.1 million, totaling $7.8 million as of June 30, 2025.
• The company has an accumulated deficit of $62.7 million as of June 30, 2025.
• Management concluded there is substantial doubt about the company's ability to continue as a going concern for at least one year from the report's issuance date due to ongoing losses and cash burn.
• Quoin regained Nasdaq compliance on April 29, 2025, following a 1-for-35 reverse ADS split on April 9, 2025, but faces immediate delisting if the bid price falls below $1.00 before April 9, 2026.
• The Netherton Syndrome research program with Queensland University of Technology (QUT) was discontinued in July 2025.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including widening losses, substantial cash burn, and a 'going concern' warning. While clinical programs are advancing, the immediate financial viability is highly uncertain, necessitating further capital raises under potentially dilutive terms. The Nasdaq compliance issue, though temporarily resolved, remains a recurring risk.

Positives

• Regained compliance with Nasdaq's minimum bid price requirement through a reverse ADS split.
• Lead product, QRX003, is in two pivotal registrational clinical studies for Netherton Syndrome with 5 US sites open and a 6th planned, and trials expanding internationally.
• QRX003 is also being developed for Peeling Skin Syndrome, with the first subject treated in New Zealand.
• Ongoing research collaborations for new product candidates, including QRX008 for scleroderma and topical rapamycin formulations for other rare diseases.
• Maintained effective disclosure controls and procedures and no material changes in internal control over financial reporting.

Negatives

• Significant increase in net loss for both the three-month ($3.7M vs $2.0M) and six-month ($7.5M vs $4.3M) periods ended June 30, 2025, compared to the prior year.
• Substantial doubt about the company's ability to continue as a going concern for at least one year due to accumulated deficit ($62.7M) and negative cash flows from operations ($6.3M for six months).
• Cash and cash equivalents decreased significantly to $1.7 million from $3.6 million at December 31, 2024.
• Investments decreased to $6.1 million from $10.4 million at December 31, 2024.
• No revenue generated to date, and no expectation of revenue from product sales for a number of years.
• Increased general and administrative expenses by 12.5% for the three months and 6.5% for the six months ended June 30, 2025.
• Significant related party indebtedness to officers totaling $2.6 million, with $600,000 short-term.

Risks

• Limited operating history and the difficulties encountered by a small developing company.
• History of losses and need for additional capital to fund operations, with no assurance of obtaining it on acceptable terms or at all.
• Substantial doubt about the ability to continue as a going concern.
• Lack of revenue and potential inability to be profitable.
• Uncertainties of cash flows and inability to meet working capital needs.
• Ability to obtain regulatory approvals.
• Ability to generate favorable pre-clinical and clinical trial results.
• Ability to identify and develop potential product candidates.
• Additional costs or delays associated with unsuccessful clinical trials.
• Inability to predict the timing of revenue from sales of a future product.
• Extensive regulatory requirements and future developmental and regulatory challenges even if product approval is obtained.
• Ability to obtain or maintain orphan drug designation or data exclusivity for product candidates.
• Potential oversight of programs or product candidates that may be more profitable or successful.
• Manufacturing processes may not be validated and methodology may not be accepted by the scientific community.
• Ability to conduct clinical trials due to difficulties enrolling patients or other reasons.
• Requirements of being a publicly traded company may strain resources.
• Potential adverse effects from failure to maintain effective internal controls.
• Ability to comply with applicable continued listing requirements of Nasdaq, especially given the recent reverse split and the rule regarding immediate delisting determination if the bid price falls below $1.00 before April 9, 2026.
• Potential negative impact on securities price and trading volume if analysts do not publish reports or adversely change recommendations.
• Potential volatility of the market price for ADSs.
• Potential dilution of shareholders' ownership due to future issuances of share capital.
• Requirement for holders of ADSs to act through the depositary to exercise their rights.
• Potential limitations on ADS holders with respect to the transfer of their ADSs.
• Risks of securities class action litigation.
• Dependence on several third-party suppliers, including single-source suppliers for CRO services, active pharmaceutical ingredient (API), and drug product manufacturing.
• Unanticipated or higher than expected clinical trial costs.
• Uncertainty of market acceptance for products, if approved.
• Inability to develop or manufacture future products at acceptable cost and performance characteristics, or successfully market them.

Future Outlook

The company expects to continue incurring significant expenses and increasing operating losses for the foreseeable future as it advances clinical development of QRX003 and other product candidates, prepares for potential marketing approvals, and builds commercialization infrastructure. It does not anticipate generating revenue from product sales for a number of years and will require substantial additional financing to fund operations and complete research and development programs. The company is assessing the impact of the recently signed One Big Beautiful Bill Act (OBBBA) on its financial statements.

Management Comments

• "Our mission is to develop and commercialize proprietary therapeutic drug products that treat rare and orphan diseases, particularly those where none currently exists."
• "We do not expect to generate revenue from product sales unless and until we successfully complete development and obtain marketing approval for one or more of our product candidates, which we expect will take a number of years and is subject to significant uncertainty."
• "Accordingly, we will need to raise additional capital prior to the commercialization of QRX003 or any other product candidate."
• "Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to continue our operations."
• "There can be no assurance that we will be able to maintain compliance with Nasdaqs Minimum Bid Price Requirement for continued listing."
• "If we are unable to obtain additional funding when it becomes necessary, the development of our product candidates will be impacted and we would likely be forced to delay, reduce, or terminate some or all of our development programs or cease operations altogether, all of which could have a material adverse effect on our business, results of operations and financial condition."

Industry Context

Quoin Pharmaceuticals operates in the highly capital-intensive and high-risk biopharmaceutical sector, specifically targeting rare and orphan diseases. This niche often benefits from expedited regulatory pathways and market exclusivity incentives (like Orphan Drug Designation) due to unmet medical needs. However, it also entails significant R&D costs, prolonged clinical trial periods, and high uncertainty regarding regulatory approvals and commercial success. The company's focus on multiple rare disease indications (Netherton Syndrome, Peeling Skin Syndrome, Scleroderma, lymphatic/venous malformations, angiofibromas) aligns with a strategy to diversify pipeline risk within the orphan drug space, but also increases overall R&D expenditure. The reliance on third-party CROs and single-source suppliers is common in this industry but introduces supply chain and operational risks.

Comparison to Industry Standards

• The company's current stage, with no commercialized products and no revenue, is typical for a late-stage clinical biopharmaceutical company.
• The accumulated deficit of $62.7 million and ongoing net losses are standard for companies in the drug development phase, as significant capital is required for R&D before potential commercialization. For example, many small-cap biotech companies like Krystal Biotech (KRYS) or BridgeBio Pharma (BBIO), also focused on rare diseases, incurred substantial losses for years before achieving profitability or significant revenue.
• The cash burn rate of $6.3 million in operating activities for six months is high relative to the $7.8 million in cash and investments, indicating a short cash runway, which is a common challenge for development-stage biotechs. Companies like Sarepta Therapeutics (SRPT), while larger, also faced significant cash burn during their Duchenne muscular dystrophy drug development phases.
• The need for additional capital and the "going concern" warning are frequent disclosures for small, pre-revenue biotechs, highlighting the inherent financial risk. This is a common theme across the sector, where companies often rely on continuous equity raises or partnerships to fund operations.
• The 1-for-35 reverse ADS split to maintain Nasdaq listing is a common tactic for small-cap companies facing minimum bid price deficiencies, seen in various biotech firms struggling with low stock prices. Its effectiveness in long-term compliance and investor confidence varies.

Related Party Transactions

• Indebtedness to Dr. Myers and Ms. Carter (officers/founders) totaling approximately $2.6 million as of June 30, 2025, for unpaid compensation and reimbursements. Repayments of $25,000 per month to each.
• Estimated liability of $1,146,251 from 2020 Notes, with $339,000 owed to two related party noteholders.

Stakeholder Impact

• Shareholders face potential for significant dilution from future equity raises and risk of delisting from Nasdaq, which would negatively impact liquidity and share value. Continued losses and going concern warning pose a risk of substantial loss of investment.
• Employees' continued operations are dependent on securing additional funding, implying potential job insecurity if funding is not obtained.
• Future customers could benefit from the development of treatments for rare and orphan diseases if successful.
• Suppliers and creditors face risk of delayed or non-payment if the company cannot secure additional funding and continue as a going concern. Dependence on single-source suppliers creates concentration risk.

Next Steps

• Complete late-stage clinical testing of QRX003 in Netherton Syndrome.
• If QRX003 clinical trials are successful, file for marketing approval in the United States and other territories.
• Prepare to commercialize QRX003 by establishing own sales infrastructure in the U.S. and Europe.
• Enter into distribution partnerships in other territories (Canada, Australia/New Zealand, Middle East, China, Hong Kong, Taiwan, Latin America, Central and Eastern Europe, Turkey, Singapore).
• Pursue business development activities by seeking partnering, licensing, merger and acquisition opportunities to expand pipeline.
• Open a sixth US clinical site for QRX003 at Northwestern University.
• Expand QRX003 pediatric study to include additional children with NS in Spain, the United Kingdom, and potentially other countries.
• Schedule a meeting with Queensland University of Technology (QUT) to discuss the future direction of the Scleroderma research program (QRX008).
• Assess the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements.
• Hold Annual General Meeting of Shareholders on August 21, 2025, to approve options granted to directors.

Key Dates

Recommendation

The filing highlights severe financial distress, including widening losses, significant cash burn, and an explicit "going concern" warning. While the company has active clinical programs for rare diseases, the immediate financial outlook is highly precarious, necessitating substantial capital raises that will likely be dilutive. The Nasdaq listing compliance, though temporarily resolved, remains a significant risk. Given the high burn rate relative to current cash and investments, and the fundamental uncertainty about continued operations, the risk-reward profile is highly unfavorable for investors.

Keywords

Pharmaceuticals, Biotechnology, Rare Diseases, Orphan Diseases, Netherton Syndrome, QRX003, Clinical Trials, Drug Development, SEC Filing, 10-Q, Going Concern, Nasdaq Listing, Scleroderma, Peeling Skin Syndrome, Rapamycin, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibromas